Type 2 diabetes (T2D) patients think the regular use of self-monitoring of blood glucose (SMBG) can keep their blood sugar levels under control. Self-monitoring of blood glucose (SMBG) is a procedure which involves a finger-prick blood test to read blood sugar levels from an instrument. Expected benefits with the use of self-monitoring of blood glucose (SMBG) methods are
A study done by researchers at the University of North Carolina, United States shows no benefits to type 2 (non-insulin-dependent) diabetes patients with routine blood glucose testing or finger-prick blood tests. Researchers conducted studies to find out improvement in hemoglobin A1c levels and health-related quality of life (HRQOL) with self-monitoring of blood glucose (SMBG) procedure among 450 type 2 (non-insulin-dependent) diabetes patients with an average age of 61 years. Self-monitoring of blood glucose (SMBG) procedure being followed by about 75 percent of patients. Duration of the study was 1 year.
At the end of the study, the study results show no significant difference in health-related quality of life (HRQOL) and hemoglobin A1c levels with the use of self-monitoring of blood glucose (SMBG). The study also shows no difference in the incidents of hospitalizations, emergency visits, low blood sugar levels (or hypoglycemia) and instances of starting insulin therapy during the study period. No benefits with the use of self-monitoring of blood glucose (SMBG) and the costs may outweigh the benefits. Senior author of the study was Dr. Katrina Donahue, at the School of Medicine, the University of North Carolina, Chapel Hill, United States. The study findings were published in the JAMA Internal Medicine, under the title Glucose Self-monitoring in Non-Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings.
An earlier study done in 2012 shows 20 percent enhanced risk of breast cancer in women with diabetes. A study done by Taiwanese researchers at Chung Shan Medical University, Taichung City, Taiwan suggests a reduction to breast cancer risk of diabetic women with long-term use of low-dose aspirin apart from reducing the risk of cardiovascular diseases.
Researchers have done 14 years follow up studies with 148,739 diabetic women from the Taiwan National Health Insurance Research Database by administering a low dose of aspirin (75 to 165 mg) medicine per day. The follow-up study shows
But researchers failed to find out the mechanism behind the reduction in breast cancer risk with low, medium or cumulative doses of aspirin medication. Author of the study was Dr. Yi-Sun Yang, from the Chung Shan Medical University, Taichung, Taiwan. The study findings were published in the Journal of Women's Health, under the title Low-Dose Aspirin Reduces Breast Cancer Risk in Women with Diabetes: A Nationwide Retrospective Cohort Study in Taiwan.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.